This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record. Numerical trial results on this page are restricted to the results posted in the ClinicalTrials.gov record; calculations added by Clinical Biostats are labelled as such.
1. Trial at a Glance
This page covers the registry results for Spectroscopy Versus Standard Care in Cervical Cancer Patients (NCT00529464), a randomized phase 3 study. The primary outcome is Number of Unnecessary Loop Electrosurgical Excision Procedures (LEEP).
| Feature | Registry value |
|---|---|
| ClinicalTrials.gov identifier | NCT00529464 |
| Phase | Phase 3 |
| Condition | Cervical Cancer |
| Allocation | Randomized |
| Design model | Parallel |
| Masking | None (open label) |
| Enrollment | 2 |
| Arms in the primary outcome | n/a |
| Lead sponsor | M.D. Anderson Cancer Center |
| Results posted | Yes |
2. Clinical Question
Population
The registry describes a diagnostic study involving patients with cervical intraepithelial neoplasia and stratification by outside Pap smear findings of low-grade or high-grade squamous intraepithelial lesions. The listed condition is Cervical Cancer. Further eligibility details are not reported in the registry record.
Intervention
The planned diagnostic approach included colposcopy with fluorescence spectroscopy. The study description also refers to multispectral digital colposcopy, used retrospectively, and to follow-up evaluations that could include Pap testing, endocervical curettage, and biopsy.
Comparator
The principal diagnostic comparison was colposcopy alone versus colposcopy with spectroscopy. The primary outcome description also identifies a three-arm comparison that includes colposcopy with a LEEP procedure. The exact operational role of that arm is not further clarified in the registry record.
Primary question
The stated primary endpoint was the number of unnecessary LEEPs up to 2 years. A LEEP was classified as unnecessary when histological examination resulted in a diagnosis of low-grade squamous intraepithelial lesion or normal tissue. The registry says this outcome could not be assessed because no subject received randomized treatment assignment.
The study's broader diagnostic objective was to examine whether optical spectroscopy could improve specificity over colposcopy alone. That question is related to, but not identical to, counting unnecessary LEEPs. Specificity concerns how often a diagnostic approach correctly identifies people without the target condition; unnecessary LEEP counts concern procedures followed by particular histological findings. Neither diagnostic accuracy nor comparative effects can be established from the registry record because randomized treatment assignment did not occur and the primary outcome was not assessed.
3. Trial Design
The registry describes a Phase 3 randomized, parallel-group trial with no masking. Its planned arms were colposcopy, colposcopy with fluorescence spectroscopy, and colposcopy with a LEEP procedure. The primary outcome description frames the comparison as three arms, while the study summary emphasizes comparing colposcopy with colposcopy plus spectroscopy. The record does not explain in detail how the LEEP arm fit into the randomized diagnostic comparison.
The study was intended to evaluate diagnostic procedures in patients stratified according to outside Pap smear findings of low-grade and high-grade squamous intraepithelial lesions. The summary also describes multispectral digital colposcopy for retrospective use. Planned assessments could involve clinically or quantitatively read Pap tests, biopsy results, point-probe spectroscopy, and digital colposcopy imaging. These are objectives and planned assessments, not reported results.
The registry lists enrollment as 2, but also states that no subject received randomized treatment assignment. The primary outcome could therefore not be assessed. The study status is terminated. The recorded start is 2006-11 and primary completion is 2008-08. These record entries do not establish that randomized comparisons or the planned follow-up assessments were completed.
The registry does not report the method used to generate an allocation sequence, allocation concealment, masking of outcome assessors, or a detailed statistical analysis plan. It also does not report the reason for termination. Those omissions limit the extent to which the intended design can be evaluated beyond the broad design labels and descriptions recorded.
4. Participant Flow and Accounting
The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.
Before assignment: Two patients were recruited, both ineligible, with no research related procedures performed. Study terminated early due to low enrollment.
Overall Study
| Stage | Colposcopy | Colposcopy + Fluorescence Spectroscopy | Colposcopy + LEEP |
|---|---|---|---|
| STARTED | 0 | 0 | 0 |
| COMPLETED | 0 | 0 | 0 |
| NOT COMPLETED | 0 | 0 | 0 |
Analysis population for the primary outcome, as defined in the registry: The primary outcome measure could not be assessed because no subject received randomized treatment assignment. The study was terminated.
5. Baseline Characteristics
The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.
| Characteristic | Unit | Colposcopy | Colposcopy + Fluorescence Spectroscopy | Colposcopy + LEEP | Total |
|---|---|---|---|---|---|
| Participants analysed | 0 | 0 | 0 | 0 | |
| Sex: Female, Male: Female | Participants | — | — | — | — |
| Sex: Female, Male: Male | Participants | — | — | — | — |
6. Primary Endpoint
The registry lists the primary outcome as Number of Unnecessary Loop Electrosurgical Excision Procedures (LEEP), measured over Up to 2 years.
| Element | Registry entry |
|---|---|
| Result type | N/A |
| Measure of spread | not applicable |
| Unit | not stated |
| Endpoint classification | not reduced to a single comparison |
The primary endpoint was the number of unnecessary Loop Electrosurgical Excision Procedures (LEEP) up to 2 years. Under the registry definition, a LEEP counted as unnecessary if histological examination resulted in low-grade squamous intraepithelial lesion or normal tissue. The endpoint was intended to connect a diagnostic pathway with a consequential procedure and the histology found after that procedure.
This kind of endpoint can be useful when a study asks whether a diagnostic strategy is associated with procedures that do not yield the specified higher-grade finding. It differs from a direct measure of diagnostic accuracy: it counts procedures under a histological rule rather than reporting sensitivity or specificity. The study summary separately states an objective of examining whether spectroscopy improves specificity over colposcopy alone, but no diagnostic accuracy estimates are reported in the registry record.
The endpoint is specified for a period of up to 2 years. The record does not give an observed count, a group-specific estimate, or a comparison estimate. It explicitly states that the primary outcome could not be assessed because no subject received randomized treatment assignment. Consequently, the registry record does not show whether the endpoint occurred or how it differed across the planned arms.
7. Why No Re-analysis Is Shown
8. Statistical Interpretation
The central interpretive fact is that the intended randomized comparison did not yield an assessable primary outcome. The registry states that no subject received randomized treatment assignment and that the study was terminated. Although enrollment is listed as 2, that entry should not be read as evidence that two participants were assigned to the planned arms or contributed outcome data. The record does not report an analyzed population for the primary endpoint.
No primary outcome count, treatment-effect estimate, confidence interval, or p-value is reported in the registry record. There is therefore no posted estimate from which to judge the size, direction, or precision of a difference in unnecessary LEEPs. The trial cannot be interpreted as showing a benefit, lack of benefit, or equivalence between the diagnostic approaches. It also cannot establish whether spectroscopy changed specificity or the number of procedures performed.
In general, a confidence interval describes a range of effect estimates compatible with the data and the statistical model; its width reflects uncertainty as well as the amount and variability of information available. Here, there is no primary comparison estimate or confidence interval in the record to interpret. Likewise, a p-value would address compatibility between data and a specified null model, but no primary analysis or p-value is reported. The absence of a reported test is not evidence that a test found no difference.
The listed adverse-event groups record zero at risk and zero affected for serious and other adverse events. Those entries do not provide a comparative safety assessment when the record also says no subject received randomized treatment assignment. Deaths are not reported in the registry record. The adverse-event fields should therefore not be interpreted as evidence that the procedures had no adverse effects in a treated trial population.
The study objectives and intervention descriptions indicate what investigators intended to examine, not what the trial demonstrated. The registry's diagnostic rationale cannot substitute for outcome results. Any claims about performance, patient-level consequences, or differences between arms would require data and analyses not reported in the registry record.
9. Statistical Methods Explained
The registry identifies a randomized, parallel-group design without masking. In a randomized trial, assignment by chance is intended to make treatment groups comparable on average, including with respect to characteristics that may affect outcomes. A parallel design assigns participants to a group and compares outcomes across groups. These are general features of the design; in this study, the registry states that no subject received randomized treatment assignment, so the planned randomized comparison was not carried out as an analyzable comparison.
What would the primary comparison estimate?
The primary outcome was the number of LEEPs classified as unnecessary under the registry's histological definition. A comparison across arms would ordinarily require a clear analysis population, a consistent outcome definition, and a method for comparing the outcome between assigned groups. The registry does not report a primary analysis, group-specific outcome counts, or an effect estimate. It also does not describe whether the intended analysis would use counts, proportions, or another summary. No particular analysis method can be attributed to the trial from this record.
In general, an estimate of a treatment effect summarizes the observed contrast between groups, while its uncertainty depends on the available observations and the analysis assumptions. A confidence interval conveys uncertainty around such an estimate. A hypothesis test and p-value address a different question: how compatible the data are with a specified null hypothesis under a statistical model. Neither an estimate nor its uncertainty is reported for the primary outcome in the registry record.
How should the planning assumptions be read?
The registry describes a planning illustration based on a stated fraction of an observed effect, with a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation. It specifies that non-time-to-event illustrations are expressed as participants per arm, while time-to-event illustrations use a total number of events. These are general planning conventions, not evidence that the trial enrolled or analyzed those numbers of participants. The sample sizes in any such illustration are planning quantities, not observed power.
Power is a design quantity tied to assumptions about an effect, variability, significance level, allocation, and analysis. It is not a measure of the probability that a particular result is true after data have been observed. The registry does not report a sample-size justification for the actual trial or an observed primary effect estimate. The described planning assumptions therefore do not establish that the study was adequately sized, nor can they be used to infer the result of the unassessed endpoint.
Why can diagnostic specificity and unnecessary procedures differ?
In general, specificity describes how often a diagnostic test correctly classifies people who do not have the target condition. An unnecessary-procedure endpoint instead counts procedures meeting a stated post-procedure histological rule. The measures may be related, but one does not directly determine the other. A complete assessment of specificity would require diagnostic classifications and a suitable reference standard, along with a defined analysis. The registry does not report such estimates.
Over-dispersion is a general concern when count outcomes vary more than a chosen statistical model expects. If present, it can make standard errors too small under a model that assumes less variability, leading to overly narrow confidence intervals or misleading tests. The registry does not report a count distribution, model, or assessment of over-dispersion for the primary endpoint. It would therefore be inappropriate to claim that this issue was tested or that a particular correction was used.
What does the record allow statistically?
The record supports a description of the planned trial and the reason the primary outcome was unavailable: no subject received randomized treatment assignment. It does not support a recalculated comparison, because no primary summary statistics are reported. No analysis method, adjustment, interim analysis, or handling rule for multiple outcomes is reported in the registry record. The record's statement that a planned outcome could not be assessed takes precedence over any attempt to infer a result from the design description or enrollment entry.
10. Multiplicity, Missing Data and Analysis Populations
The study summary describes several diagnostic assessments and objectives, including Pap test readings, biopsy readings, point-probe fluorescence and reflectance spectroscopy, multispectral digital colposcopy, and the objective of improving specificity over colposcopy alone. The primary outcome description separately identifies unnecessary LEEPs. When a study has several outcomes, measurements, or comparisons, multiplicity can arise because repeated testing increases the chance of at least one apparently notable result. In general, an analysis plan can specify which outcome is primary and whether or how other tests will be adjusted or interpreted.
The registry identifies a primary outcome but does not report a multiplicity strategy, a hierarchy among secondary outcomes, or a detailed statistical analysis plan. The number of analyses is recorded as 0. The primary endpoint could not be assessed because no subject received randomized treatment assignment; accordingly, no outcome comparisons are reported. The record does not establish whether any adjustment for multiple comparisons was planned.
Missing-data handling is also not reported in the registry record. The lack of an assessable primary outcome is attributed to the absence of randomized treatment assignment, not to a stated pattern of missing observations within randomized groups. The record does not give follow-up completion, reasons for missing measurements, or an imputation or sensitivity-analysis approach. An analysis population, such as an intention-to-treat population, is not described. It would be unsupported to characterize the endpoint as missing at random, to infer that participants were excluded after assignment, or to claim that a particular missing-data method was used.
These omissions matter because multiplicity and missingness can influence how estimates and tests should be interpreted. In this record, however, the more fundamental limitation is that the randomized primary comparison was not available to analyze.
11. What the Result Does, and Does Not, Mean
The registry record documents a planned randomized diagnostic study and identifies an intended primary outcome: unnecessary LEEPs, defined using post-procedure histology and assessed up to 2 years. It also records the study's broader aim of evaluating spectroscopy in comparison with colposcopy, including an objective concerning diagnostic specificity. These descriptions clarify the questions the study was designed to address.
The record does not report a result for the primary endpoint. It states that the outcome could not be assessed because no subject received randomized treatment assignment, and it lists the study status as terminated. There are no reported group-level counts or estimates to establish whether one planned approach was associated with more or fewer unnecessary procedures. No conclusion about diagnostic specificity can be drawn from the objectives alone.
In general, an unassessed outcome is not the same as an outcome with a null or statistically nonsignificant result. A null finding would require analyzed data and a defined comparison that did not show persuasive evidence of a difference under the chosen method. The registry record reports no such analysis. It therefore cannot support conclusions of benefit, no benefit, equivalence, or harm for any planned arm.
The record also does not provide a basis for comparing adverse events between groups. The listed fields show zero at risk and zero affected in each group, while the randomized assignment statement indicates that there was no treated randomized population for the planned comparison. This combination should be read as a limitation of the available record, not as proof of no adverse effects.
In practical statistical terms, the information supports an account of intent and study status, not an estimate of comparative performance. The absence of reported outcome data leaves the primary question unanswered in the registry record.
12. Why This Trial Matters Statistically
This trial is statistically informative chiefly as an example of the difference between a study's planned question and an answer supported by analyzed data. The registry describes a randomized comparison and a clinically interpretable endpoint, but also states that no subject received randomized treatment assignment. Without assigned groups and an assessable primary outcome, the intended comparison cannot yield an effect estimate in the record.
The distinction matters because design labels alone do not ensure that a randomized analysis occurred. Randomization can support causal interpretation when participants are assigned and outcomes are analyzed according to an appropriate plan. When assignment does not occur, the benefits of that design cannot be assumed. A registry entry listing an enrollment value does not resolve this issue; the record's explicit statement about randomized treatment assignment is central to interpreting the study.
The endpoint also illustrates why diagnostic accuracy and downstream clinical actions need separate definitions. Specificity concerns classification against a reference standard, whereas unnecessary LEEP counts procedures meeting a histological criterion. A trial might intend to study both, but results for one cannot be substituted for the other. Here, neither comparative endpoint result is reported.
Finally, the record shows why planning assumptions should remain separate from evidence. A sample-size illustration based on an assumed fraction of an observed effect is not an outcome analysis and is not observed power. With no reported primary comparison, such planning language cannot fill the evidentiary gap. The statistically appropriate conclusion is limited: the planned question is identifiable, but the registry record does not provide an answer.
13. Limitations
- The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
- Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.
The principal trial-specific limitation is explicit: the primary outcome could not be assessed because no subject received randomized treatment assignment. The study status is terminated, and the registry reports no primary outcome counts, group estimates, or analyses. This prevents interpretation of the planned randomized comparison.
The enrollment entry is 2, but the record does not explain how that entry relates to screening, enrollment, treatment exposure, or the absence of randomized assignment. It should not be treated as an analyzed sample size for either arm. The reason for termination is not reported in the registry record.
The record does not provide allocation-generation or concealment details, outcome-assessor masking, a complete protocol, or a statistical analysis plan. Although the trial is labeled unmasked, the masking status of individual outcome assessments is not separately described. The planned role of the colposcopy-plus-LEEP arm is not fully explained, despite its inclusion in the primary outcome's three-arm comparison.
The study summary refers to multiple diagnostic measurements and follow-up assessments, but no results for those assessments are reported. Follow-up completion, missing-data patterns, analysis populations, multiplicity procedures, and reasons for missing outcome information are not described. The record also gives different wording in its titles: the registered short title refers to cervical cancer, while the official title refers to cervical intraepithelial neoplasia. The record does not resolve that difference. These limits constrain interpretation to the stated objectives and status rather than comparative findings.
14. Related Tutorials
15. Related Statistical Calculators
16. Sources
- ClinicalTrials.gov: Spectroscopy Versus Standard Care in Cervical Cancer Patients — NCT00529464.
- Registry record last updated 2016-05-09; status last verified 2012-12.
- Results first posted 2010-12-08.
- Data retrieved from ClinicalTrials.gov on 2026-11-09.
- Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.
Continue through the Clinical Biostats statistical pathway
Use this trial's endpoint as a starting point for deeper study of effect measures, confidence intervals, and sample-size planning.
17. Record Summary
The registry describes a Phase 3, randomized, parallel-group study without masking, sponsored by M.D. Anderson Cancer Center. The planned diagnostic approaches included colposcopy, colposcopy with fluorescence spectroscopy, and a colposcopy-plus-LEEP arm. The study aimed to assess unnecessary LEEPs and to investigate whether optical spectroscopy could improve diagnostic specificity over colposcopy alone.
The recorded start is 2006-11, primary completion is 2008-08, and status is terminated. Enrollment is listed as 2. The registry states that no subject received randomized treatment assignment, so the primary outcome could not be assessed. No primary analysis or comparative outcome estimate is reported in the registry record.